Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy.
Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, Wang Y, Han M, Shi C, Tang C, Sun P, Zhang R, Fu Z, Zhang J, Zhu D, Chen C, Jiang X.
J Control Release. 2023 Aug;360:718-733. doi: 10.1016/j.jconrel.2023.07.021. Epub 2023 Jul 19.
NIPBL::NACC1 Fusion Hepatic Carcinoma.
Hissong E, Al Assaad M, Bal M, Reed KA, Fornelli A, Levine MF, Gundem G, Semaan A, Orr CE, Sakhadeo U, Manohar J, Sigouros M, Wilkes D, Sboner A, Montgomery EA, Graham RP, Medina-Martínez JS, Robine N, Fang JM, Choi EK, Westerhoff M, Delgado-de la Mora J, Caudell P, Yantiss RK, Papaemmanuil E, Elemento O, Sigel C, Jessurun J, Mosquera JM.
Am J Surg Pathol. 2024 Feb 1;48(2):183-193. doi: 10.1097/PAS.0000000000002159. Epub 2023 Dec 4.
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma.
Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L.
Front Immunol. 2021 May 7;12:650486. doi: 10.3389/fimmu.2021.650486. eCollection 2021.
The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.
Huang JH, Wang J, Chai XQ, Li ZC, Jiang YH, Li J, Liu X, Fan J, Cai JB, Liu F.
Microbiol Spectr. 2022 Oct 26;10(5):e0098322. doi: 10.1128/spectrum.00983-22. Epub 2022 Sep 29.
Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery.
Sun L, Ke X, Guan A, Jin B, Qu J, Wang Y, Xu X, Li C, Sun H, Xu H, Xu G, Sang X, Feng Y, Sun Y, Yang H, Mao Y.
Clin Transl Med. 2023 Jul;13(7):e1331. doi: 10.1002/ctm2.1331.
In situ Thermal-Responsive Magnetic Hydrogel for Multidisciplinary Therapy of Hepatocellular Carcinoma.
Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, Li M, Chen S, Fang WW, Dong L, Xuan S, He T, Cao B, Lu Y.
Nano Lett. 2022 Mar 23;22(6):2251-2260. doi: 10.1021/acs.nanolett.1c04413. Epub 2022 Mar 7.
Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues.
He Y, Zhang Q, Yu X, Zhang S, Guo W.
J Transl Med. 2023 Feb 2;21(1):68. doi: 10.1186/s12967-023-03938-6.
A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, Zhou C, Zhang Y, Chen B, Bo Z, Li J, Yu H, Wang Y, Chen G.
Gut Microbes. 2023 Jan-Dec;15(1):2201159. doi: 10.1080/19490976.2023.2201159.
M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.
Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, Cao M, Cai J, Wu J, Wang X.
J Hematol Oncol. 2020 Jan 8;13(1):5. doi: 10.1186/s13045-019-0839-x.
MiR-126 in Hepatocellular Carcinoma and Cholangiocellular Carcinoma: A Reappraisal with an in situ Detection of miR-126.
Zailaie SA, Sergi CM.
Ann Clin Lab Sci. 2022 Jan;52(1):73-85.
